ALNM Holds Gains Over Five Days

by admin

Alnylam Pharmaceuticals reported exciting stage 3 clinical trial results on September 20. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year.

 

Sonal sent out a level 2 alert at 7 am, and the next trade was at $93.50 during pre-market trading. The stock continued to surge throughout the day to a peak of $114.32. During the next four trading days, ALNM continued to trade in a range of $112-116.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!

Interested in events that actually move the market?Awesome!

Let us send you a recap of every weeks market movers!

Better yet…Receive ALERTS
of Market Moving Events…
seconds after they surface!

  • Mergers & Acquisitions
  • Clinical Trials
  • Contract Awards
  • Stock Repurchase Programs
  • Earnings Announcement

Get Started